We listen,
learn, and
deliver.
To those lacking effective treatment options: We hear you. And we are relentlessly driving toward much-needed solutions.
Tisento is Italian for “I hear you.”
At Tisento, we believe meaningful innovation starts with listening.
We listen to those living with serious diseases to understand the impact of disease on their lives. We also listen to families, clinicians, regulatory agencies, and scientific data. These inputs shape how we conduct our research, design our trials, and evolve our company.
We are on a mission to deliver medicines that address what matters most.
Now Enrolling!
Our Commitment to MELAS:
Understanding & Addressing the Unmet Need
Short for Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes, MELAS affects multiple organ systems, especially organs with high energy demands like the brain and muscles. This results in severe and burdensome symptoms including chronic physical and mental fatigue, memory and other cognitive issues, muscle weakness, exercise intolerance, headaches, seizures, and stroke-like episodes. MELAS is also associated with a shortened life expectancy.
We are committed to advancing zagociguat as a meaningful treatment for people living with MELAS.
Adolescent MELAS Interview Study
We want to hear from teens (ages 12-17 years) with MELAS to understand their experiences of living with MELAS.
Zagociguat:
Building on Encouraging Phase 2a Data in MELAS Patients
Our investigational medicine, zagociguat, is an oral, once-daily, first-in-class, brain-penetrant soluble guanylate cyclase (sGC) stimulator. Zagociguat acts directly on a pathway that is dysregulated in MELAS and that plays an essential role in fundamental physiological processes.
Zagociguat mechanism of action: sGC stimulation
In a Phase 2a study in patients with MELAS, zagociguat showed:
Excellent safety profile
Exposure in the central nervous system
Evidence of improvements in mitochondrial and neuronal function
Increased blood flow in the brain
News
About Us
We are a committed team of industry veterans working closely with a broad network of collaborators. Our current focus is on developing zagociguat as a treatment for individuals with MELAS, a debilitating disease with no effective treatments. At Tisento, our goal is to enable a better future for those living with severe diseases.